

# ASX Release

---

## SUDA APPOINTS DAVID SIMMONDS TO THE BOARD

**PERTH, AUSTRALIA – 27 March 2019:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, has appointed David Simmonds to the Board as a non-executive Director, effective 27 March 2019.

David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several high-profile businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle.

David was a member of the Australian Auditing and Assurance Standards Board (AUASB) from 2006 to 2013. The AUASB is the statutory agency of the Australian Government that is responsible for developing, issuing and maintaining auditing and assurance standards. As a member of this body David oversaw the introduction of legally enforceable auditing standards in Australia and the move to harmonisation with international standards.

David is currently a member of the Board and chairs the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia.

SUDA's CEO, Mr Stephen Carter, commented: "We are very pleased to welcome David to the Board of SUDA as a non-executive director. David brings a wealth of knowledge and experience, having had exposure to a range of companies as a senior partner at Ernst & Young and will be a key player in supporting the continuing growth of the business."



**Further information:**  
**STEPHEN CARTER**  
**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**  
**SUDA Pharmaceuticals Ltd**  
Tel: +61 8 6142 555  
[sjcarter@sudapharma.com](mailto:sjcarter@sudapharma.com)

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety; and cancer.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)